GENSCRIPT B-1K: Associate Legend Biotech Schedules Six Presentations on CAR-T Portfolio for ASH 2026

Bulletin Express11-05

Hong Kong, 5 November 2026—GENSCRIPT B-1K (HKEX: 01548) reported that its U.S.–listed associate, Legend Biotech Corporation, has filed a Form 6-K with the U.S. Securities and Exchange Commission announcing a broad scientific presence at the 68th American Society of Hematology (ASH) Annual Meeting to be held 12–15 December 2026 in New Orleans.

Key disclosures • Legend Biotech will deliver two oral presentations, two poster presentations and one e-publication featuring CARVYKTI (ciltacabtagene autoleucel) data in multiple myeloma. • Additional pipeline updates include: – A poster on LUCAR-G39D, an anti-CD20/CD19 dual-CAR allogeneic γδ T-cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma. – A poster on LB2501, an in-vivo CD19/CD20 dual-targeting CAR-T therapy in its first-in-human study for the same indication.

Regulatory context The Form 6-K was filed on 4 November 2026 (New York time) after Hong Kong market hours. All statements concerning future development or therapeutic potential are forward-looking and subject to the usual uncertainties outlined in Legend’s risk disclosures.

Board statement The announcement was issued voluntarily by GENSCRIPT B-1K’s Board, chaired by Robin Meng, to keep shareholders informed of material developments at its associate company.

Investors are advised to exercise caution when dealing in GENSCRIPT B-1K’s securities in light of the forward-looking nature of the disclosed information.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment